Mutation Carrier Screening: Clinical Trials

4 trials of Mutation Carrier Screening, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 unknown. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Recruiting 2, Active not recruiting 1, Unknown 1

Follow Mutation Carrier Screening: new trials by email Literature Review of Mutation Carrier Screening trials Research Report on Mutation Carrier Screening

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)20002024-06-182026-11-02
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)29002023-04-072026-11-18
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13
Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men
physiologic testing, study of socioeconomic and demographic variables, evaluation of cancer risk factors - Prostate Cancer
Phase 2UnknownLawrence Livermore National Laboratory at University of California8002002-03-012013-09-20

Conditions studied

Central Nervous System Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Ependymoma (1)  ·  Fallopian Tube Neoplasms (1)  ·  Glioma (1)  ·  Hepatoblastoma (1)  ·  Histiocytic Sarcoma (1)  ·  Histiocytosis, Langerhans-Cell (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Medulloblastoma (1)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Neoplasm Metastasis (1)  ·  Neuroblastoma (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Lawrence Livermore National Laboratory at University of California (1)

Countries

United States (4)  ·  Puerto Rico (3)  ·  Canada (2)  ·  Australia (1)

Top investigators

Donald W Parsons (1)  ·  James M Ford (1)  ·  Jerald P Radich (1)  ·  Kenneth T. Bogen, DrPH, MPH, MA, ScD (1)

Results publications

PMID 33591402, PMID 35353553, PMID 36902217, PMID 41166674, PMID 42686334

NIH funding

U10CA180820 (1), U10CA180886 (1), U10CA180888 (1)